Navigation Links
Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO)
Date:7/27/2009

those projected. Factors that may affect GSK' s operations are described under 'Risk Factors' in the 'Business Review' in the company' s Annual Report on Form 20-F for 2008.

    CONTACT: Amgen, Thousand Oaks
    David Polk, 805-447-4613 (media)
    Arvind Sood, 805-447-1060 (investors)


    Enquiries GSK:
    UK Media enquiries:                   Philip Thomson      (020) 8047 5502
                                          David Outhwaite     (020) 8047 5502
                                          Stephen Rea         (020) 8047 5502
                                          Alexandra Harrison  (020) 8047 5502

    US Media enquiries:                   Nancy Pekarek        (919) 483 2839
                                          Mary Anne Rhyne      (919) 483 2839
                                          Kevin Colgan         (919) 483 2839
                                          Lisa Behrens         (919) 483 2839

    European Analyst/Investor enquiries:  David Mawdsley      (020) 8047 5564
                                          Sally Ferguson      (020) 8047 5543
                                          Gary Davies         (020) 8047 5503

    US Analyst/ Investor enquiries:       Tom Curry            (215) 751 5419
                                          Jen Hill Baxter      (215) 751 7002


(1) Secular data

(2) Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporosis Int. 2006; 17(12):1726-33

(Logo: http://www.newscom.com/cgi-bin/prnh/20081015/AMGENLOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20090724/GSKLOGO)


'/>"/>
SOURCE Amgen; GlaxoSmithKline
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Amgen and Genentech Brace Themselves for Heavy Pressure From Biogenerics Manufacturers
2. More Than 230 Cyclists to Ride in Amgen California Coast Classic Bike Tour to Raise $1.3 Million for Arthritis Foundation
3. Entry of Biogenerics and Decreasing Use of Amgens Epogen and Johnson & Johnsons Procrit Will Cause a $2.8 Billion Decline in the Drug Market for Chemotherapy-Induced Anemia by 2016
4. Oxford Genome Sciences and Amgen to Jointly Discover Novel Therapeutic Antibodies in Cancer
5. Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharmas Fall Line Up!
6. Co-Inventor of Amgens Aranesp(R) Technology Directs Worldwide Patent Strategy for Diffusion Pharmaceuticals First-in-Class Oxygen Enhancing Therapeutics
7. Amgen Announces Webcast of 2008 Third Quarter Financial Results
8. Amgens Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23
9. Call for Applications: The Amgen Award for Science Teaching Excellence
10. Amgen to Webcast 2008 Business Review Meeting on November 7 From Millennium Hotel in New York
11. Amgen Positioned to Deliver Attractive Growth Over Next Five Years
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 2014  Now available is a stem cell therapy ... Therapies , located in Guadalajara, Mexico ... a new health option: stem cell therapies for ... patients suffer from joint and muscle injuries due to ... torn rotator cuff, tennis elbow, and knee injuries. Throughout ...
(Date:7/24/2014)... team led by group leader Yung-Eun Sung has ... synthesize sulfur-doped and nitrogen-doped graphenes which can be ... and fuel cells. Yung-Eun Sung is both a ... at Institute for Basic Science* (IBS) and a ... achievement has great significance with regards to the ...
(Date:7/24/2014)... 24, 2014 Research and Markets ... Culture Market 2014-2018" report to their offering.  ... culture is the in vitro growth of plant or ... studies, and biopharmaceutical production. Cell culture is a crucial ... instruments and cell culture consumables are necessary for the ...
(Date:7/24/2014)...  CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical ... for the prevention and treatment of cardiorenal and ... July 18, 2014 from the NYSE MKT LLC ... plan to regain compliance with continued listing standards ... is continuing the Company,s listing and has granted ...
Breaking Biology Technology:Stem Cells In Sports Injuries, Joints And Muscular Pain 2Stem Cells In Sports Injuries, Joints And Muscular Pain 3Global Cell Culture Market 2014-2018: Key Vendors are Becton, Dickinson and Co, EMD, GE Healthcare, Lonza Group, Sigma Aldrich and Thermo Fisher Scientific 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 3
... Schering-Plough Assumes Exclusive Worldwide Marketing Rights for ... N.J., May 19 Schering-Plough Corporation (NYSE: ... to its global collaboration with Novartis for ... therapies for the treatment of asthma and ...
... May 18 Solvay Pharmaceuticals announces it ... a company specialized in enabling and accelerating global ... China. Through this agreement, Solvay Pharmaceuticals will gain ... specifically on compounds in the cardiovascular area. ...
... Entire ALS Community to Join a Nationwide Network of ... ALS Therapy Development Institute (ALS TDI) announced its ... designed to increase the awareness and understanding of ALS ... To accomplish its goal, the campaign brings together three ...
Cached Biology Technology:Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD 2Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD 3Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD 4Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD 5Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD 6Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD 7Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD 8Solvay Pharmaceuticals Announces Strategic Partnership With HUYA to Access new Drug Candidates From China 2Solvay Pharmaceuticals Announces Strategic Partnership With HUYA to Access new Drug Candidates From China 3Campaign to Increase the Awareness and Understanding of Lou Gehrig's Disease Reaches 22 U.S. States 2Campaign to Increase the Awareness and Understanding of Lou Gehrig's Disease Reaches 22 U.S. States 3
(Date:7/24/2014)... new study has identified two factors that characterize ... the production of highly qualified physics teachers. Specifically, ... champion physics teacher education in combination with institutional ... remain viable. Science, Technology, Engineering and Math (STEM) ... the study points the way for institutions seeking ...
(Date:7/24/2014)... Some sticky research out of York University shows ... species of toxic grass fungus: moose saliva (yes moose ... Letters , "Ungulate saliva inhibits a grassendophyte mutualism" shows ... fescue grass (which hosts a fungus called epichlo festucae ... growth and less toxicity. , "Plants have evolved defense ...
(Date:7/24/2014)... at Albert Einstein College of Medicine of ... J. Fox Foundation for Parkinson,s Research to translate a ... This drug discovery project will test chemical compounds on ... a drug that acts on an underlying cause of ... help many people manage their symptoms, we are eager ...
Breaking Biology News(10 mins):Creating sustainable STEM teacher preparation programs 2Moose drool inhibits growth of toxic fungus: York U research 2Albert Einstein College of Medicine receives grant from the Michael J. Fox Foundation to fund drug discovery project targeting Parkinson's 2Albert Einstein College of Medicine receives grant from the Michael J. Fox Foundation to fund drug discovery project targeting Parkinson's 3
... are elementary building blocks of life. They often perform ... to fold into three-dimensional structures. Misfolding of proteins leads ... strategies did nature develop over the course of evolution ... chemist Dr. Frauke Grter (Heidelberg Institute for Theoretical Studies) ...
... January 31, 2013 -- Deborah E. Wiley, Chair of ... JWa & JWb), announced today that the twelfth annual ... Dr. Michael Young, Rockefeller University, Dr. Jeffrey Hall, Brandeis ... The Wiley Prize is being awarded to Dr. Young, ...
... N.C. In the last decade, a new strain of ... everyone at risk of contracting the dangerous bacterial infection. This ... a chunk of genes not shared by any other strains, ... the bacteria to survive and persist in the community. ...
Cached Biology News:Protein origami: Quick folders are the best 2Protein origami: Quick folders are the best 312th annual Wiley Prize in Biomedical Sciences awarded 212th annual Wiley Prize in Biomedical Sciences awarded 3UNC study may lead to treatments that are effective against all MRSA strains 2
... ShortCut RNase III, used with its manganese-containing ... a heterogeneous mix of short (1825 bp) ... in mammalian cells. 1.3 units (1 l) ... convert 1 g of dsRNA into siRNA ...
EZ-Tn5™ Transposase is designed for use with our pMOD™ series of vectors as well as any EZ-Tn5™ transposon system....
HIV Reverse Transcriptase provides an excellent target for evaluating antiviral agents or catalyzing error prone synthesis on RNA and DNA templates....
OmniSlide thermal Cycler for slide applications. 20 slide capacity. Humidity Chamber. Slide Rack can be transferred directly to Wash Module to avoid handling individual slides....
Biology Products: